Comment from Pharmaceutical Research and Manufacturers of America (PhRMA)

Summary: Pharmaceutical Research Manufacturers of America (PhRMA) supports the FDA's draft guidance on master protocols for drug and biological product development, noting it aligns with previous recommendations and mandates. They suggest specific improvements, such as expanding the discussion on basket trials, clarifying combination therapy scope, and refining definitions for substudies and informed consent.